# Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

> **NCT05667064** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1200 (actual)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05667064
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-09
- **Primary completion:** 2025-07-21
- **Final completion:** 2025-07-21
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05667064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05667064, "Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05667064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*